ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience1998
Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 183 citations in OpenAlex.
- Galanin Receptors in the Central Nervous System: Exploring Ligand Interactions, Signal Transduction, and Potential Clinical Implications.Molecules (Basel, Switzerland) · 2026Review
- Article
- Persistent ∆FosB expression limits recurrent seizure activity and provides neuroprotection in the dentate gyrus of APP mice.Progress in neurobiology · 2024Article
- Introduction to the special issue on status epilepticus: neuronal injury, plasticity, and therapies; Celebrating the legacy of Dr. Claude G. Wasterlain.Epilepsia open · 2023Article
- Preferential Gs protein coupling of the galanin GalPharmacological research · 2022Article
- Galanin analogs prevent mortality from seizure-induced respiratory arrest in mice.Frontiers in neural circuits · 2022Article
- Insights into Potential Targets for Therapeutic Intervention in Epilepsy.International journal of molecular sciences · 2020Review
- Effects of galanin receptor 2 and receptor 3 knockout in mouse models of acute seizures.Epilepsia · 2018Article
- Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2.Neurochemical research · 2017Article
- Status Epilepticus and Beyond: A Clinical Review of Status Epilepticus and an Update on Current Management Strategies in Super-refractory Status Epilepticus.Korean journal of critical care medicine · 2017Review
- Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy.Experimental neurology · 2017Article
- Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics.Epilepsia · 2017Article
- Altered gene expression profile in a mouse model of SCN8A encephalopathy.Experimental neurology · 2017Article
- Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment.Annals of the New York Academy of Sciences · 2016Review
- Differential Effect of Neuropeptides on Excitatory Synaptic Transmission in Human Epileptic Hippocampus.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Glutamatergic Mechanisms Associated with Seizures and Epilepsy.Cold Spring Harbor perspectives in medicine · 2015Review
- Regulation of glucose and insulin release following acute and repeated treatment with the synthetic galanin analog NAX-5055.Neuropeptides · 2015Article
- Neuropeptides as targets for the development of anticonvulsant drugs.Molecular neurobiology · 2014Review
- Brain galanin system genes interact with life stresses in depression-related phenotypes.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Pathogenesis of epilepsy: challenges in animal models.Iranian journal of basic medical sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
We examined the role of hippocampal galanin in an animal model of status epilepticus (SE). Control rats showed abundant galanin-immunoreactive (Gal-IR) fibers in the dentate hilus, whereas no Gal-IR neurons were observed. Three hours after the onset of self-sustaining SE (SSSE), induced either by intermittent stimulation of the perforant path for 30 min (PPS) or by injection of lithium and pilocarpine, Gal-IR fibers disappeared in the hilus and remained absent for up to 1 week afterward. Twelve hours after the induction of SE by PPS or 3 hr after pilocarpine administration, Gal-IR neurons appeared in the hilus; these neurons increased in number after 1 d and gradually declined 3 and 7 d later. Galanin concentration in the hippocampus, measured by ELISA, significantly decreased on the plateau of SSSE and increased 24 hr after PPS. Galanin (0.05 nmol) injected into the hilus prevented the induction of SSSE, and 0.5 nmol of galanin stopped established SSSE. These effects were attenuated by galanin receptor antagonists (M35 > M40 >/= M15). 2-Ala-galanin (5 nmol), a putative agonist of galanin type 2 receptors, prevented but was unable to stop SSSE. M35 facilitated the development of SSSE when given before PPS. We suggest that hippocampal galanin acts as an endogenous anticonvulsant via galanin receptors. SE-induced galanin depletion in the hippocampus may contribute to the maintenance of seizure activity, whereas the increase of galanin concentration and the appearance of galanin-immunoreactive neurons may favor the cessation of SSSE. The seizure-protecting action of galanin SSSE opens new perspectives in the treatment of SE.
Indexed as
Identifiers
9822761PMC6793305W1750845513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.